ADVANCE SALES Clause Samples

The Advance Sales clause establishes the terms under which a seller may receive payment for goods or services before they are delivered or performed. Typically, this clause outlines the conditions for advance payment, such as the timing, amount, and method of payment, and may specify what happens if the goods or services are not ultimately provided. By setting clear expectations for both parties, the clause helps ensure that the seller secures necessary funds upfront while providing the buyer with defined obligations and protections, thereby reducing the risk of non-payment or non-delivery.
ADVANCE SALES. Except as agreed to by the parties, no advance sales of tickets shall occur for the event. If advance sales are permitted by MSDPT, the Pre-Event Invoice will identify the manner and venues at which such advance sales of tickets shall occur, including, but not limited to, a short accurate description of the event including telephone number and e-mail for ticket sales or ticketing related questions, length of event, official name of event, and any other information pertinent to event ticketing prior to the first day of public ticket sales.
View SourceView Similar (6)
ADVANCE SALES. The Lessee shall provide the MSDWC with a name, daytime telephone number and e- mail for the contact person for advance sales unless ticket sales are to occur through the ▇▇▇▇▇▇ Auditorium.
View SourceView Similar (3)
ADVANCE SALES. The Lessee shall provide the MSDPT with a name, daytime telephone number and e-mail for the contact person for advance sales unless ticket sales are to occur through the PPAC Box Office.
View SourceView Similar (2)
ADVANCE SALES. Notwithstanding the provisions of Section 2 above, the Company may, in order to expedite the issuance of any New Securities (the “Offered Securities”), issue all of the Offered Securities to one or more Persons (the “Initial Subscribing Stockholders”), without complying with the provisions of Section 2 above, provided that either (i) the Initial Subscribing Stockholders agree to offer to sell to each applicable RFO Holder but not Initial Subscribing Stockholders (such applicable RFO Holders being hereinafter referred to as the “Other Stockholders”) its respective Pro Rata Portion of the Offered Securities (calculated as provided in Section 2.1 above) on the same terms and conditions as issued to the Initial Subscribing Stockholders; provided, however, that the purchase price payable by the Other Stockholders to the Initial Subscribing Stockholders for the Offered Securities may include (A) an amount equal to any accrued and unpaid dividends thereon (if applicable), or (B) a reasonable rate of interest, in each case calculated from the date such Initial Subscribing Stockholders purchased such Offered Securities through the date of sale to the Other Stockholders, or (ii) the Company shall offer to sell an additional amount of Offered Securities to the Other Stockholders only in an amount and manner which provides the Other Stockholders with rights substantially similar to the rights outlined in Section 2.1 above; provided further, until the closing of the purchase of the Offered Securities by the Initial Subscribing Stockholders, the Company shall be prohibited from taking actions that adversely affects the rights of the Other Stockholders as the holders of the Offered Securities, including but not limited to any issuance of dividends, distributions or modifications to classes of equity. The Initial Subscribing Stockholders or the Company, as applicable, shall offer to sell such Offered Securities to the Other Stockholders within forty-five (45) days after the closing of the purchase of the Offered Securities by the Initial Subscribing Stockholders.
View Source

Related to ADVANCE SALES

  • Advance Payments The Employer agrees to issue advance payments of estimated net salary for vacation periods of two (2) or more complete weeks, providing a written request for such advance payment is received from the employee at least six (6) weeks prior to the last pay before the employee’s vacation period commences, and providing the employee has been authorized to proceed on vacation leave for the period concerned. Pay in advance of going on vacation shall be made prior to departure. Any overpayment in respect of such pay advances shall be an immediate first charge against any subsequent pay entitlement and shall be recovered in full prior to any further payment of salary.

  • Eligible Expenditures 1. Subject to Article 8.7 of the Regulation, eligible expenditures of this Programme are: (a) management costs of the Programme Operator in accordance with the detailed budget in the financial plan; (b) payments to projects within this Programme in accordance with the Regulation, this programme agreement and the project contract. 2. Eligible expenditures of projects are those actually incurred by the Project Promoter or project partners, meet the criteria set in Article

  • Product Sales Subject to Sections 10.3(c) and 10.3(d), Licensee agrees that it will not sell, offer for sale, or assist third parties (including Affiliates) in selling Product except for the sale and offer for sale of (A) TAF Product, TAF Combination Product, TDF Product and TDF Combination Product for use in the Field and in the countries of the TDF-TAF Territory, (B) COBI Product and COBI Combination Product for use in the Field and in the countries of the COBI Territory, and (C) EVG Product, EVG Combination Product and Quad Product for use in the Field and in the countries of the EVG-Quad Territory.‌ (i) Licensee agrees that during the period in which the Patents are valid and enforceable (on a Product-by-Product basis) it will prohibit its Distributors from selling Product (A) to any other wholesaler or distributor, (B) outside the Territory for which Licensee is licensed for sale of such Product pursuant to Section 2.2, or (C) for any purpose outside the Field. (ii) Licensee agrees that it will not administer the TAF Quad to humans, or sell the TAF Quad until Gilead has obtained marketing approval for the TAF Quad from the FDA. Licensee agrees that it will not administer EVG to humans, or sell Products containing EVG until Gilead has obtained marketing approval for an EVG Product from the FDA. Licensee agrees that it will not administer COBI to humans, or sell Products containing COBI until Gilead has obtained marketing approval for a COBI Product from the FDA. Licensee agrees that it will not administer TAF to humans, or sell Products containing TAF until Gilead has obtained marketing approval for a TAF Product from the FDA. If Gilead obtains marketing approval from the FDA for any Quad Product or a Combination Product containing TAF, COBI or EVG (“Approved Combination Product”) prior to obtaining marketing approval for a TAF Product, EVG Product or COBI Product from the FDA, then Licensee will be allowed to administer such Quad Product or such Approved Combination Product to humans, and sell such Quad Product or such Approved Combination Product from and after the date of such marketing approval from the FDA, but will not (A) administer to humans or sell Combination Products containing EVG other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for an EVG Product, or (B) administer to humans or sell Combination Products containing COBI other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a COBI Product or (C) administer to humans or sell Combination Products containing TAF other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a TAF Product.

  • Advance Payment The right to indemnification conferred in this Article VII shall include the right to be paid or reimbursed by the Company the reasonable expenses incurred by a Person of the type entitled to be indemnified under Section 7.3 who was, is or is threatened to be made a named defendant or respondent in a Proceeding in advance of the final disposition of the Proceeding and without any determination as to the Person’s ultimate entitlement to indemnification; provided, however, that the payment of such expenses incurred by any such Person in advance of the final disposition of a Proceeding shall be made only upon delivery to the Company of a written affirmation by such Person of his or her good faith belief that he has met the standard of conduct necessary for indemnification under Article VII and a written undertaking, by or on behalf of such Person, to repay all amounts so advanced if it shall ultimately be determined that such indemnified Person is not entitled to be indemnified under this Article VII or otherwise.

  • Eligible expenditure 6.1 Eligible expenditure consists of payments by the Recipient for the Purpose. Eligible expenditure is net of VAT recoverable by the Recipient from HM Revenue & Customs and gross of irrecoverable VAT. 6.2 The Recipient shall account for the Grant on an accruals basis. This requires the cost of goods or services to be recognised when the goods or services are received, rather than when they are paid for.